A retrospective, observational cohort study analyzing effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 01 Mar 2023 New trial record
- 01 Mar 2023 Results published in the Scandinavian Journal of Gastroenterology